nach oben

Die Gastroenterologie

Erschienen in:

30.11.2023 | Schwerpunkt

Gender-Medizin bei chronisch entzündlicher Darmerkrankung

Ist das von Bedeutung?

verfasst von: Dr. Elena Sonnenberg, Alica Kubesch-Grün

Erschienen in: Die Gastroenterologie | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auch heute noch werden geschlechtsspezifische Unterschiede in Bezug auf Genetik, Krankheitsphänotyp und Behandlungsmodalitäten bei chronisch entzündlicher Darmerkrankung (CED) in der Praxis zu wenig berücksichtigt. Dies ist insbesondere von Bedeutung für die Therapieadhärenz und das Auftreten von Komplikationen. Die Relevanz des Geschlechts zeigt sich auch im Hinblick auf die Interpretation von Studiendaten. Mögliche Faktoren für die Begünstigung einer CED sind eine Antibiotikaexposition bei Jungen oder eine Appendektomie bei Frauen. Bei positiver Familienanamnese für eine CED sind Frauen mit größerer Wahrscheinlichkeit betroffen als bei sporadischen Fällen. Das geschlechtsspezifische Auftreten von extraintestinalen Manifestationen ist gut belegt. Sowohl beim M. Crohn (MC) als auch bei der Colitis ulcerosa (CU) kommt es bei Frauen eher zu einer verzögerten Diagnosestellung und zu Fehldiagnosen als bei Männern. Allerdings weisen Männer mit CED ein höheres Risiko auf, an einem kolorektalen Karzinom zu erkranken, als Frauen mit CED. Bei der medikamentösen Therapie ergaben Studien, dass Männer sowohl bei MC als auch bei CU häufiger mit immunsuppressiven Medikamenten oder mit Biologika behandelt wurden als Frauen. Depressionen, Angststörungen, Essstörungen und sexuelle Funktionsstörungen kommen zwar auch bei männlichen CED-Patienten vor, werden aber bei Frauen wesentlich häufiger diagnostiziert.

Brahme F, Lindström C, Wenckert A (1975) Crohn’s disease in a defined population. An epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmö, Sweden. Gastroenterology 69:342–351PubMed

Kyle J (1992) Crohn’s disease in the northeastern and northern isles of Scotland: an epidemiological review. Gastroenterology 103:392–399PubMed

Latour P, Louis E, Belaiche J (1998) Incidence of inflammatory bowel disease in the area of Liège: a 3 years prospective study (1993–1996). Acta Gastroenterol Belg 61:410–413PubMed

Leong RWL, Lau JY, Sung JJY (2004) The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis 10:646–651PubMed

Ng SC et al (2013) Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 62:630PubMed

Shivananda S et al (1987) Epidemiology of Crohn’s disease in Regio Leiden, the Netherlands. A population study from 1979 to 1983. Gastroenterology 93:966–974PubMed

Wagtmans MJ, Verspaget HW, Lamers CBHW, van Hogezand RA (2001) Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol 96:1541–1546PubMed

Prideaux L, Kamm MA, Cruz PPD, Chan FKL, Ng SC (2012) Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 27:1266–1280PubMed

Yang S‑K, Loftus EV, Sandborn WJ (2001) Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 7:260–270PubMed

10.

Shah SC et al (2018) Sex-based differences in incidence of inflammatory bowel diseases—pooled analysis of population-based studies from western countries. Gastroenterology 155:1079–1089.e3PubMed

11.

Virta L, Auvinen A, Helenius H, Huovinen P, Kolho K‑L (2012) Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease—a nationwide, register-based Finnish case-control study. Am J Epidemiol 175:775–784PubMed

12.

Shaw SY, Blanchard JF, Bernstein CN (2010) Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105:2687–2692PubMed

13.

Andersson RE, Olaison G, Tysk C, Ekbom A (2003) Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 124:40–46PubMed

14.

Lakatos PL et al (2013) Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 19:1010–1017PubMed

15.

Biedermann L et al (2015) High rates of smoking especially in female Crohn’s disease patients and low use of supportive measures to achieve smoking cessation—data from the Swiss IBD cohort study. J Crohns Colitis 9:819–829PubMed

16.

Severs M et al (2018) Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies. Inflamm Bowel Dis 24:1298–1306PubMed

17.

Jacenik D et al (2019) Sex- and age-related estrogen signaling alteration in inflammatory bowel diseases: modulatory role of estrogen receptors. Int J Mol Sci 20:3175PubMedPubMedCentral

18.

Ortizo R et al (2017) Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 29:1064–1070PubMed

19.

Khalili H et al (2013) Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut 62:1153PubMed

20.

Khalili H et al (2016) Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology 150:1561–1567.e1PubMed

21.

Kane SV, Reddy D (2008) Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterology 103:1193–1196

22.

Zelinkova Z et al (2012) Maternal imprinting and female predominance in familial Crohn’s disease. J Crohns Colitis 6:771–776PubMed

23.

Lin Z et al (2010) Genetic association of nonsynonymous variants of the IL23R with familial and sporadic inflammatory bowel disease in women. Digest Dis Sci 55:739–746PubMed

24.

Tedde A et al (2008) Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner. Scand J Gastroenterol 43:712–718PubMed

25.

Vermeire S, Satsangi J, Peeters M, Parkes M, Jewell D, Vlietinck R, Rutgeerts P (2001) Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. Gastroenterology 120:834–840PubMed

26.

Vadstrup K et al (2020) Extraintestinal manifestations and other comorbidities in ulcerative colitis and Crohn disease: a Danish nationwide registry study. Crohn’s Colitis 360 2:otaa70PubMedPubMedCentral

27.

Park S‑K et al (2021) Extraintestinal manifestation of inflammatory bowel disease in Asian patients: a multinational study. Dig Liver Dis 53:196–201PubMed

28.

Karmiris K et al (2016) Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis 10:429–436PubMed

29.

Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106:110–119PubMed

30.

Algaba A et al (2021) Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the ENEIDA registry. Digest Dis Sci 66:2014–2023PubMed

31.

Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96:1116–1122PubMed

32.

Fraga M et al (2017) Primary sclerosing cholangitis in the Swiss inflammatory bowel disease cohort study. Eur J Gastroenterol Hepatol 29:91–97PubMed

33.

Greenstein AJ et al (1992) Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine 71:261–270PubMed

34.

Ampuero J, Rojas-Feria M, Castro-Fernández M, Cano C, Romero-Gómez M (2014) Erythema nodosum and pyoderma gangrenosum. J Gastroenterol Hepatol 29:291–295PubMed

35.

Kumar S, Pollok R, Goldsmith D (2022) Renal and urological disorders associated with inflammatory bowel disease. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izac140CrossRefPubMedCentral

36.

Wu X et al (2013) Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 7:e171–e177PubMed

37.

Sempere L et al (2023) Gender biases and diagnostic delay in inflammatory bowel disease: multicenter observational study. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izad001CrossRefPubMedPubMedCentral

38.

Lee D et al (2017) Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol 23:6474–6481PubMedPubMedCentral

39.

Mazor Y et al (2011) Prediction of disease complication occurrence in Crohn’s disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis 5:592–597PubMed

40.

Blumenstein I et al (2011) Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity. A subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 5:203–210PubMed

41.

Bokemeyer B et al (2013) Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 7:355–368PubMed

42.

Yamamoto T et al (2023) Diagnosis and clinical features of perianal lesions in newly diagnosed Crohn’s disease: subgroup analysis from inception cohort registry study of patients with Crohn’s disease (iCREST-CD). J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjad038CrossRefPubMedPubMedCentral

43.

Wada Y et al (2015) Risk factors for decreased bone mineral density in inflammatory bowel disease: a cross-sectional study. Clin Nutr 34:1202–1209PubMed

44.

Walldorf J et al (2013) Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohns Colitis 7:901–907PubMed

45.

Bartram SA et al (2006) Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol 12:5680–5686PubMedPubMedCentral

46.

Robinson RJ et al (1998) Osteoporosis and determinants of bone density in patients with Crohn’s disease. Digest Dis Sci 43:2500–2506PubMed

47.

Haschka J et al (2016) High-resolution quantitative computed tomography demonstrates structural defects in cortical and trabecular bone in IBD patients. J Crohns Colitis 10:532–540PubMedPubMedCentral

48.

Gupta S, Wu X, Moore T, Shen B (2013) Frequency, risk factors, and adverse sequelae of bone loss in patients with ostomy for inflammatory bowel diseases. Inflamm Bowel Dis 20:259–264

49.

Söderlund S et al (2010) Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 138:1697–1703.e2PubMed

50.

Jess T, Rungoe C, Peyrin–Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645PubMed

51.

Caso V et al (2010) Gender differences in patients with acute ischemic stroke. Womens Health 6:51–57

52.

Shaw LJ et al (2008) Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American college of cardiology–national cardiovascular data registry. Circulation 117:1787–1801PubMed

53.

Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF (2012) Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 10:82PubMedPubMedCentral

54.

Oliver JE, Silman AJ (2009) Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 11:252PubMedPubMedCentral

55.

Szalat A, Auryan S, Raz I, Itamar R (2008) Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab 10:1135–1156PubMed

56.

Schmetzer O, Flörcken A (2012) Sex and gender differences in pharmacology. Handb Exp Pharmacol. https://doi.org/10.1007/978-3-642-30726-3_19CrossRefPubMed

57.

Heath EM, Kim RB, Wilson A (2022) A comparative analysis of drug therapy, disease phenotype, and health care outcomes for men and women with inflammatory bowel disease. Digest Dis Sci 67:4287–4294PubMed

58.

Greuter T et al (2020) Gender differences in inflammatory bowel disease. Digestion 101:98–104PubMed

59.

Billioud V, Sandborn WJ, Peyrin-Biroulet L (2011) Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 106:674–684PubMed

60.

Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J (2012) Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: a large single centre experience. J Crohns Colitis 6:143–153PubMed

61.

Lie MRKL, Kreijne JE, van der Woude CJ (2016) Sex is associated with adalimumab side effects and drug survival in patients with Crohn’s disease. Inflamm Bowel Dis 23:75–81

62.

Nasuno M, Miyakawa M, Tanaka H, Motoya S (2017) Short- and long-term outcomes of Infliximab treatment for steroid-refractory ulcerative colitis and related prognostic factors: a single-center retrospective study. Digestion 95:67–71PubMed

63.

Agrawal M et al (2022) Gender-based differences in response to tumor necrosis factor inhibitor therapies for ulcerative colitis: individual participant data meta-analyses of clinical trials. Inflamm Bowel Dis 29:1–8PubMedCentral

64.

Zelinkova Z et al (2012) Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J Gastroenterol 18:6967–6973PubMedPubMedCentral

65.

Schultheiss JPD et al (2019) Earlier discontinuation of TNF‑α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Aliment Pharmacol Ther 50:386–396PubMed

66.

Hawthorne AB, Rubin G, Ghosh S (2008) Review article: medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 27:1157–1166PubMed

67.

Long MD et al (2012) Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA partners): methodology and initial results. Inflamm Bowel Dis 18:2099–2106PubMed

68.

Mantzaris GJ et al (2007) How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission? Inflamm Bowel Dis 13:446–450PubMed

69.

Yen L, Wu J, Hodgkins P, Cohen RD, Nichol MB (2012) Medication use patterns and predictors of nonpersistence and nonadherence with oral 5‑aminosalicylic acid therapy. J Manag Care Pharm 18:701–712PubMed

70.

Zelante A, Giorgi AD, Borgoni R, Trevisani L, Gallerani M (2014) Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol 60:269–274PubMed

71.

Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L (2013) Adherence to anti-TNF therapy in inflammatory bowel diseases. Inflamm Bowel Dis 19:1528–1533PubMed

72.

Cruz PD et al (2015) Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients—a POCER study analysis. Aliment Pharmacol Ther 42:867–879PubMed

73.

Peyrin-Biroulet L et al (2012) Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol 107:1693–1701PubMedPubMedCentral

74.

Samuel S et al (2013) Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 19:1858–1866PubMed

75.

Targownik LE, Singh H, Nugent Z, Bernstein CN (2012) The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 107:1228–1235PubMed

76.

Rottoli M, Remzi FH, Shen B, Kiran RP (2012) Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Dis 14:336–341PubMed

77.

Wu X et al (2016) Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg 20:631–639PubMed

78.

Bommena S, Goldberg A, Amini M, Alishahi Y (2022) Depression in women with inflammatory bowel disease: a multifaceted approach for a multidimensional problem. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izac245CrossRef

79.

Marafini I et al (2020) High frequency of undiagnosed psychiatric disorders in inflammatory bowel diseases. J Clin Med 9:1387PubMedPubMedCentral

80.

Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC (2021) Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:359–370PubMed

81.

Siu AL et al (2016) Screening for depression in adults: US preventive services task force recommendation statement. JAMA 315:380–387PubMed

82.

Farraye FA, Melmed GY, Lichtenstein GR, Kane SV (2017) ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 112:241–258PubMed

83.

Vigod SN et al (2019) Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut 68:1597PubMed

84.

Rivière P et al (2017) Frequency of and factors associated with sexual dysfunction in patients with inflammatory bowel disease. J Crohns Colitis 11:1347–1352PubMed

85.

Beese SE, Harris IM, Moore D, Dretzke J (2018) Body image dissatisfaction in patients with inflammatory bowel disease: a systematic review protocol. Syst Rev 7:184PubMedPubMedCentral

86.

McDermott E et al (2015) Body image dissatisfaction. Inflamm Bowel Dis 21:353–360PubMed

87.

van der Have M et al (2014) Determinants of health-related quality of life in Crohn’s disease: a systematic review and meta-analysis. J Crohns Colitis 8:93–106PubMed

88.

Bel LGJ et al (2015) Sexual dysfunctions in men and women with inflammatory bowel disease. J Sex Med 12:1557–1567PubMed

89.

Timmer A, Bauer A, Dignass A, Rogler G (2007) Sexual function in persons with inflammatory bowel disease: a survey with matched controls. Clin Gastroenterol Hepatol 5:87–94PubMed

90.

O’Toole A, Winter D, Friedman S (2014) Review article: the psychosexual impact of inflammatory bowel disease in male patients. Aliment Pharmacol Ther 39:1085–1094PubMed

91.

Feagins LA, Kane SV (2009) Sexual and reproductive issues for men with inflammatory bowel disease. Am J Gastroenterology 104:768–773

92.

Allocca M et al (2018) Sexual and reproductive issues and inflammatory bowel disease. Eur J Gastroenterol Hepatol 30:316–322PubMed

93.

Shin T, Okada H (2016) Infertility in men with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 7:361PubMedPubMedCentral

94.

Heetun ZS, Byrnes C, Neary P, O’Morain C (2007) Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 26:513–533PubMed

95.

Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM (2009) Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 15:720–725PubMed

96.

de Lima A, Zelinkova Z, Mulders AGMGJ, van der Woude CJ (2016) Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 14:1285–1292.e1PubMed

97.

Sands K, Jansen R, Zaslau S, Greenwald D (2015) Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment Pharmacol Ther 41:821–834PubMed

98.

Laube R et al (2020) Knowledge and attitudes towards pregnancy in females with inflammatory bowel disease: an international, multi-centre study. J Crohns Colitis 14:1248–1255PubMed

99.

Selinger CP et al (2013) Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 7:e206–e213PubMed

100.

Cosnes J, Nion-larmurier I, Afchain P, Beaugerie L, Gendre J (2004) Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2:41–48PubMed

101.

Schreiner P et al (2021) Fatigue in inflammatory bowel disease and its impact on daily activities. Aliment Pharmacol Ther 53:138–149PubMed

Titel: Gender-Medizin bei chronisch entzündlicher Darmerkrankung
Ist das von Bedeutung?
verfasst von: Dr. Elena Sonnenberg
Alica Kubesch-Grün
Publikationsdatum: 30.11.2023
Verlag: Springer Medizin
Erschienen in: Die Gastroenterologie / Ausgabe 6/2023
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-023-00738-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Gender-Medizin bei chronisch entzündlicher Darmerkrankung

Ist das von Bedeutung?

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Neue Therapien bei chronisch entzündlicher Darmerkrankung: „nibs“, „mabs“ und „mods“

Mitteilungen des Verein Netzwerk gegen Darmkrebs e. V.

CME: Funktionelle Magen-Darm-Erkrankungen

Mitteilungen der NDGG

Metabolom und Mikrobiom

Mitteilungen der Stiftung LebensBlicke

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin